Michael Stiles, MD
Glaucoma Specialist · Overland Park, KSNPI 1356390546
Payments from drug & device makers
Across 508 payments — averaging $961.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$247K
- AbbVie$160K
- Aerie Pharmaceuticals, Inc.$31K
- Alcon Research LLC$31K
- Alcon$15K
- Ivantis, Inc$1K
- plus $3K from 20 others
Across 3 payments — averaging $6823.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$20K
- AbbVie$70
What the payments were for
- Consulting fees$3,6329%
- Speaking & faculty fees$28,84169%
- Travel & lodging$930%
- Food & beverage$8,89421%
- Education$140%
- Gifts$450%
- Entertainment$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 126 | $247,136 |
| AbbVie(2 entities) | 201 | $160,235 |
| Aerie Pharmaceuticals, Inc. | 34 | $30,988 |
| Alcon Research LLC | 23 | $30,951 |
| Alcon | 44 | $15,425 |
| Ivantis, Inc | 3 | $1,135 |
| Sight Sciences, Inc. | 21 | $611 |
| NEW World Medical,inc. | 7 | $559 |
| Bausch & Lomb Americas Inc. | 6 | $229 |
| Sun Pharmaceutical Industries Inc. | 9 | $220 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $148 |
| Optos, Inc. | 2 | $127 |
| Thea Pharma Inc. | 5 | $110 |
| Iridex Corporation | 3 | $91 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $87 |
| Mobius Therapeutics, LLC | 1 | $86 |
| Ocular Therapeutix, Inc. | 3 | $54 |
| Tarsus Pharmaceuticals, Inc. | 2 | $50 |
| Amgen | 2 | $40 |
| Rxsight Inc | 2 | $34 |
| Novartis | 2 | $34 |
| Harrow Eye, LLC | 1 | $29 |
| Shire North American Group Inc | 1 | $25 |
| Philips North America LLC | 1 | $19 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
| Topcon Healthcare, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$23,253
- Rocklatan$23,253
- LUMIGAN$7,536
- XEN GLAUCOMA TREATMENT SYSTEM$1,883
- Hydrus Microstent$1,168
- COMBIGAN$800
- Ophthalmic Surgical Adjuncts$375
- Kahook Dual Blade$372
- Clearpath$372
- Ahmed Glaucoma Valve$372
- Streamline$372
- Via360$372
- DURYSTA$311
- OMNI(R) SURGICAL SYSTEM (US)$270
- Clareon$237
- PANORAMIC OPHTHALMOSCOPE$209
- OCT OPHTHALMOSCOPE$209
- AcrySof IQ PanOptix UV IOL$149
- AcrySof IQ VIVITY$149
- AcrySof$148
How this compares
Too few glaucoma specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 292 | $152,467 |
| CombiganBrimonidine Tartrate/Timolol | 294 | $114,287 |
| RestasisCyclosporine | 77 | $65,157 |
| Alphagan PBrimonidine Tartrate | 106 | $45,548 |
| RocklatanNetarsudil Mesylat/Latanoprost | 89 | $43,287 |
| RhopressaNetarsudil Mesylate | 79 | $30,211 |
| Prednisolone Acetate | 597 | $24,982 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,146 | $19,854 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 80 | $19,204 |
| Latanoprost | 1,356 | $16,579 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 91 | $15,508 |
| Travoprost | 72 | $14,724 |
| VyzultaLatanoprostene Bunod | 37 | $13,513 |
| XiidraLifitegrast | 14 | $11,928 |
| Brimonidine Tartrate | 459 | $11,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $160,235 | $377,458769 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $30,988 | $73,498168 claims |
| AlconSimbrinza, Azopt | $15,425 | $28,19099 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $229 | $25,44151 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $87 | $4,55922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Kansason file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Overland Park
- Ann StechschulteOverland Park$3K
- Anita CampbellWichita$79K
- Neeti AlapatiLenexa$4K
- Stephen AmbrosePrairie Village$881
- Francis SoansWichita$748
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.